Literature DB >> 15775754

Carrier screening panels for Ashkenazi Jews: is more better?

Jennifer R Leib1, Sarah E Gollust, Sara Chandros Hull, Benjamin S Wilfond.   

Abstract

PURPOSE: To describe the characteristics of Ashkenazi Jewish carrier testing panels offered by US Laboratories, including what diseases are included, the labels used to describe the panels, and the prices of individual tests compared to the prices of panels for each laboratory.
METHODS: GeneTests (http://www.genetests.org) was searched for laboratories that offered Tay-Sachs disease testing. Information was obtained from laboratory web sites, printed brochures, and telephone calls about tests/panels.
RESULTS: Twenty-seven laboratories offered up to 10 tests. The tests included two diseases associated with death in childhood (Niemann-Pick type A and Tay-Sachs disease), five with moderate disability and a variably shortened life span (Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia, and mucolipidosis type IV), and two diseases that are not necessarily disabling or routinely shorten the lifespan (Gaucher disease type I and DFNB1 sensorineural hearing loss). Twenty laboratories offered a total of 27 panels of tests for three to nine diseases, ranging in price from $200 to $2082. Of these, 15 panels cost less than tests ordered individually. The panels were described by 24 different labels; eight included the phrase Ashkenazi Jewish Disease or disorder and six included the phrase Ashkenazi Jewish Carrier.
CONCLUSION: There is considerable variability in the diseases, prices, and labels of panels. Policy guidance for establishing appropriate criteria for inclusion in panels may be useful to the Ashkenazi Jewish community, clinicians, and payers. Pricing strategies that offer financial incentives for the use of "more tests" should be reexamined.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Substances:

Year:  2005        PMID: 15775754     DOI: 10.1097/01.gim.0000156527.87525.8f

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  10 in total

1.  Prenatal whole genome sequencing: just because we can, should we?

Authors:  Greer Donley; Sara Chandros Hull; Benjamin E Berkman
Journal:  Hastings Cent Rep       Date:  2012-06-20       Impact factor: 2.683

2.  Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease.

Authors:  Sherry I Brandt-Rauf; Victoria H Raveis; Nathan F Drummond; Jill A Conte; Sheila M Rothman
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

3.  Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals.

Authors:  D Cho; M L McGowan; J Metcalfe; R R Sharp
Journal:  Hum Reprod       Date:  2013-04-14       Impact factor: 6.918

4.  Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation?

Authors:  Phillis Lakeman; Anne Marie Catharina Plass; Lidewij Henneman; Pieter Dirk Bezemer; Martina Cornelia Cornel; Leo Pieter ten Kate
Journal:  Eur J Hum Genet       Date:  2009-02-18       Impact factor: 4.246

5.  Generating a taxonomy for genetic conditions relevant to reproductive planning.

Authors:  Diane M Korngiebel; Carmit K McMullen; Laura M Amendola; Jonathan S Berg; James V Davis; Marian J Gilmore; Cary O Harding; Patricia Himes; Gail P Jarvik; Tia L Kauffman; Kathleen A Kennedy; Dana Kostiner Simpson; Michael C Leo; Frances L Lynch; Denise I Quigley; Jacob A Reiss; C Sue Richards; Alan F Rope; Jennifer L Schneider; Katrina A B Goddard; Benjamin S Wilfond
Journal:  Am J Med Genet A       Date:  2016-03       Impact factor: 2.802

6.  Prenatal healthcare providers' Gaucher disease carrier screening practices.

Authors:  Dana Falcone; Elisabeth McCarty Wood; Michael Mennuti; Sharon X Xie; Vivianna M Van Deerlin
Journal:  Genet Med       Date:  2012-05-31       Impact factor: 8.822

7.  Preconceptional genetic carrier testing and the commercial offer directly-to-consumers.

Authors:  Pascal Borry; Lidewij Henneman; Phillis Lakeman; Leo P ten Kate; Martina C Cornel; Heidi C Howard
Journal:  Hum Reprod       Date:  2011-02-28       Impact factor: 6.918

8.  Responsible implementation of expanded carrier screening.

Authors:  Lidewij Henneman; Pascal Borry; Davit Chokoshvili; Martina C Cornel; Carla G van El; Francesca Forzano; Alison Hall; Heidi C Howard; Sandra Janssens; Hülya Kayserili; Phillis Lakeman; Anneke Lucassen; Sylvia A Metcalfe; Lovro Vidmar; Guido de Wert; Wybo J Dondorp; Borut Peterlin
Journal:  Eur J Hum Genet       Date:  2016-03-16       Impact factor: 4.246

9.  Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening?

Authors:  Kim C A Holtkamp; Merel C van Maarle; Maria J E Schouten; Wybo J Dondorp; Phillis Lakeman; Lidewij Henneman
Journal:  Eur J Hum Genet       Date:  2015-05-13       Impact factor: 4.246

10.  Carrier screening in individuals of Ashkenazi Jewish descent.

Authors:  Susan J Gross; Beth A Pletcher; Kristin G Monaghan
Journal:  Genet Med       Date:  2008-01       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.